arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ATOSSA THERAPEUTICS, INC.

ATOS
$2.31 ▲ +0.06 (+2.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

ATOSSA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $20.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -32.4%
FCF / Share $-1.08
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-9.59M
↓ -42.7%
Operating Margin Operating profit as % of sales
-118.6%
↑ +32.4%
FCF / Share Free cash flow per share
$-1.08
↑ +2.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 63 quarters